Skip to main content
Medistim logo

Medistim — Investor Relations & Filings

Ticker · MEDI ISIN · NO0010159684 LEI · 5967007LIEEXZXJOX483 OL Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-10-22 Earnings Release
Country NO Norway
Listing OL MEDI

About Medistim

https://medistim.com/

Medistim is a medical technology company specializing in intraoperative quality assessment solutions. A pioneer and market leader in Transit Time Flow Measurement (TTFM), the company develops and manufactures advanced medical devices for use during surgical procedures. Its flagship MiraQ™ system uniquely combines TTFM with high-frequency ultrasound imaging, providing surgeons with real-time data to verify graft function and blood flow. This technology is applied in cardiac, vascular, and transplant surgery to enhance procedural quality control and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Presentation of third quarter results 2020 for Medistim ASA
Earnings Release Classification · 95% confidence The document text explicitly states it is a 'Presentation of third quarter results 2020 for Medistim ASA'. It contains key financial highlights for the third quarter (Sales, Operating Result, Cashflow) and mentions a dividend decision. This content structure—a summary of period results with key metrics—is characteristic of an Earnings Release (ER) or potentially an Investor Presentation (IP). Since it is a presentation summarizing results, and not a full, comprehensive report (like an IR), 'ER' (Earnings Release) is the most appropriate fit for the initial announcement of period results, even though it is presented as a 'Presentation'. The document length is very short (776 chars), suggesting it is the summary/release rather than the full accompanying materials. Q3 2020
2020-10-22 English
Medistim ASA: Resolution to distribute dividend of NOK 2.75 per share
Notice of Dividend Amount Classification · 99% confidence The document explicitly states the resolution by the Board of Medistim ASA to distribute a dividend of NOK 2.75 per share based on the 2019 financial year results. It details the total amount, the authorization source (AGM), the record date, the ex-date, and the payment date. This content directly corresponds to the definition of a Notice of Dividend Amount.
2020-10-21 English
Presentation of third quarter results 2020 for Medistim ASA
Investor Presentation Classification · 95% confidence The document text explicitly states it is a 'Presentation of third quarter results 2020' and invites investors to a 'webinar' to view these results. This strongly suggests the document is an announcement about an upcoming event where results will be presented, rather than the full results document itself (like an IR or ER). Since it is an announcement related to financial results presentation, it aligns best with the Investor Presentation (IP) category, which covers presentations for investors. Given the short length (790 chars) and the focus on scheduling a presentation/webinar, it is not the full financial report (IR) or the initial earnings release (ER).
2020-10-15 English
Notification of trade in Medistim ASA
Director's Dealing Classification · 100% confidence The document explicitly details the sale of shares by company executives (VP of Development and VP of Medical) in Medistim ASA on a specific date (August 24th). This activity—reporting personal share transactions by company directors and executives—directly matches the definition for Director's Dealing (DIRS). The document is short and contains specific transaction details, confirming it is a report of insider trading, not an announcement of a larger report.
2020-08-24 English
Presentation of second quarter and 1st half results 2020 for Medistim ASA
Investor Presentation Classification · 99% confidence The document is explicitly titled "Medistim ASA Second quarter and 1st half 2020 financial presentation" and contains detailed financial statements (Profit and loss Q2 2020, H1 2020, Balance sheet) along with operational highlights for the second quarter and first half of the year. This structure—a comprehensive review of financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report (IR). Although it is presented as a 'presentation' (which might suggest IP), the depth of the financial tables (P&L, Balance Sheet) confirms it is the formal reporting document for the interim period, not just an investor presentation summarizing strategy. It is not the Annual Report (10-K) as it covers only Q2 and H1.
2020-08-14 English
Presentation of second quarter and 1st half results 2020 for Medistim ASA
Interim / Quarterly Report Classification · 100% confidence The document is titled '2nd quarter and 1st half report for 2020' and contains detailed financial statements, including sales, EBIT, balance sheet data, and operational status by region. It follows IFRS and IAS 34 standards for interim reporting. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.